Physician profile
Luke E Johnson
NPI 1235797689
$2,779.56
in general payments reported to CMS, 2019-2025
21 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.00 · 2022: $237 · 2023: $718 · 2024: $859 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.89 | 2023-2025 | |
| Boston Scientific Corporation | $306.63 | 2022-2025 | Exalt Model D, Rotapro |
| Takeda Pharmaceuticals U.S.A., INC. | $265.09 | 2024-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $237.05 | 2023 | Dupixent |
| Gilead Sciences, INC. | $223.93 | 2023-2024 | Epclusa |
| Janssen Biotech, INC. | $172.56 | 2024-2025 | Tremfya, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $141.14 | 2025 | Cabtreo, Siliq, Jublia |
| Glaxosmithkline, LLC. | $120.06 | 2024 | Jemperli |
| Genzyme Corporation | $119.82 | 2024 | |
| Conmed Corporation | $111.82 | 2023-2024 | Conmed Biliary, Conmed Generators |
| Aimmune Therapeutics, INC. | $94.85 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $84.10 | 2023 | |
| Medtronic, INC. | $78.53 | 2024 | Interstim |
| Celltrion USA INC. | $67.44 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $62.95 | 2025 | Rezdiffra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $29.37 | 2025 | Sapien 3 Ultra Resilia |
| Mallinckrodt Hospital Products INC. | $27.41 | 2025 | Terlivaz |
| Ambu INC. | $26.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.54 | 2023 | Xifaxan |
| Ardelyx, INC. | $22.52 | 2025 | Ibsrela |
| Pfizer INC. | $20.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.